IMMX

Immix Biopharma Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth 4/10
  • Momentum 9/10
Immix Biopharma sales and earnings growth
IMMX Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y 9.41%
  • FCF Y/Y 6.24%
Immix Biopharma gross and profit margin trends
IMMX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 547.00%
Immix Biopharma net debt vs free cash flow
IMMX Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage NA

Immix Biopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗